Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.
Peptidream Inc. and Novartis Pharma AG have expanded their peptide-drug conjugate discovery collaboration announced in 2019, adding additional peptide radioligand therapies and other programs.
Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.